Modern Pharmaceutics for Cardiovascular Diseases
Materialtyp:
ArtikelUtgivningsinformation: MDPI - Multidisciplinary Digital Publishing Institute 2024Beskrivning: 1 electronic resource (226 p.)Innehållstyp: - text
- computer
- online resource
- 9783036599793
- 9783036599809
- Medicine
- ACE2
- Ang (1-7)
- COVID-19
- HDAC inhibitor
- HTN
- NHE1
- NHE11
- NLRP3 inflammasome
- Nrf2
- RAAS
- SGLT2i
- acute coronary syndrome
- angiotensin 1-7
- angiotensin receptor–neprilysin inhibitor
- angiotensin-converting enzyme-2
- antifibrotic strategies
- antioxidant
- arterial hypertension
- aspirin
- atherosclerosis
- autonomic modulation
- calcium
- cardiac fibrosis
- cardiac myosin activation
- cardiomyocyte
- cardiovascular diseases
- cell-free secretomes
- cholesterol
- colchicine
- collagen cogrinding
- contractility
- coronary artery disease
- coronary artery disease prevention
- emergent therapeutics
- empagliflozin
- endothelial barrier
- fibrosis pathways
- gastric protection
- heart failure
- inflammation
- lipids
- lipoproteins
- long-term effects
- micronization
- myofilament
- natural anti-atherosclerotic products
- nuclear factor erythroid factor 2-related factor 2
- oxidative stress
- paracrine factors
- pharmacotherapy
- prevention
- regenerative medicine
- renin-angiotensin-aldosterone system
- serine protease inhibitor
- single-cell RNA sequencing
- small dense LDL
- sodium channel
- sodium-gluc
Open Access Unrestricted online access star
Although various non-pharmaceutical strategies addressed to the primary prevention of cardiovascular diseases such as tobacco control policies, reducing the consumption of harmful food, and increasing physical activity still represent a key strategy, often they are not sufficient. Moreover, despite the availability of a plethora of pharmaceutic approaches specifically targeting mechanisms involved in cardiovascular diseases over recent years, the burden of these pathologies has only been marginally alleviated. Therefore, new pharmaceutical and non-pharmaceutical strategies are necessary for both primary and secondary prevention to reduce the burden of cardiovascular diseases. The present reprint brings together original and review articles aiming to highlight the advances in the development of modern pharmaceutics for cardiovascular diseases in recent years.
Creative Commons Licence cc by-nc-nd cc https://creativecommons.org/licenses/by-nc-nd/4.0/
eng
Freely available e-book